ASCO 2024

The search for predicitve biomarkers continues

Prognostic value of ctDNA in therapeutic strategies;…

Personalized neoadjuvant therapy for high-risk breast…

Adjuvant endocrine therapy for ER-low EBC

AI for the prediction of disease progression

ctDNA analysis in monarchE

ctDNA important for HR+ eBC?

Ribociclib is also effective in N0 HR+/HER2− EBC

Expanding T-DxD use to HER2 ultra-low - the success…

Reassuring and clarifying new data for CDK4/6…

One step closer to chemo-free therapy for HR+/HER2+…

ER-low: endocrine therapy necessary after all?

Is there still a place for endocrine therapy in HER2+…

Heterogenity of ER+ disease

Systemic therapy of HER2+ patients with brain…

Triple positive mBC - chemotherapy unnecessary?

New data on the omission of chemotherapy in young…

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Responder premenopausal

HER2+ mBC 1stL T-Dxd

Sacituzumab tirumotecan - a new powerful ADC for…

Important OS benefit with T-Dxd in HER2+ mBC

Novel ADC-ICI combination therapy

Decreasing SG related toxicity with profilatic G-CFS

Broaden T-DXD as therapy standard for HER2low and…

Expanding use of T-DxD in HER2low and HER2 ultra-low…

The ADC revolution continues - ctDNA takes the next…

T-DXD continues its impressive track record for MBC…

First-line inavolisib/placebo + palbociclib +…

Chemo-free regimen in HER2+ luminal breast cancer

Endocrine therapy with Palbociclib + Trastuzumab

CDK4/6i effective in premenopausal patients as well

Treatment beyond progression for CDK 4/6i

INAVO120 - updated results

Chemo-free, CDK4/6 inhibitor-based combination active…

Already more in the 1stL?

Sacituzumab tirumotecan – nowy aktywny koniugat w…

Importante beneficio en la supervivencia global con…

C'è ancora posto per la terapia endocrina nel BC HER2+?

Regime senza chemioterapia nel carcinoma mammario…

CDK4/6 rechallenge

Leczenie bez chemioterapii, oparte na inhibitorze…

La révolution de l'ADC se poursuit / ctDNA franchit une…

Le traitement endocrinien a-t-il encore sa place dans…

INAVO120: risultati aggiornati

Disminución de la toxicidad relacionada con la OS con…

Is the metformin story over? How to treat HFNS…

PSMA-PET CT: Ready for clinical practice or a PROMISE…

Interesting data - but not practice changing

Unlocking Insights: The ALLIANCE Trial redefining…

Deciphering EMBARK: Exploring Enzalutamide's Impact on…

Radionukleotides - the next step forward

EMBARK demonstrates the importance of HRQoL benefit in…

Important QoL data

mCRCP CYCLONE 2 study

ARASENS Post hoc analysis: Therapy after progression

Exploring the CHAARTED TRIAL: Optimizing Treatment…

mCRPC: Who benefits from which measures?

EMBARK: Quality of Life

Unveiling the Potential: PSMA-PET in Prostate Cancer…

The evolving role of PSMA-PET with new agents

Perioperative treamtent in MIBC - new data for the use…

Modified FOLFIRINOX therapy as a good option for…

Effect of an immune diet on the outcome after radical…

Preoperative use of sacituzumab govitecan

What to do with Cis Gem Nivo?

ctDNA as a biomarker in metastatic bladder cancer

Biomarkers and long-term outcomes in pts with low tumor…

MI-UC - News from EVP standard

Treatment of urachal carcinoma

ASCO 2024: Time for the rare GU tumors?

Interim analysis of the SURE-01/02 study

ASCO24: Bladder cancer highlights

The Role of Topoisomerase Inhibitors in the…

El futuro de sacituzumab govitecan

Biomarcadores y resultados a largo plazo en pacientes…

ASCO24: Bladder cancer highlights

El papel de los inhibidores de topoisomerasa en el…

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms…

Advancing Our Understanding of Biological Mechanisms…

Combination is superior to monotherapy - how do we…

The never ending saga of biomarkers

Combination therapies for chromophobe renal cell…

Belzutifan in earlier lines in advanced ccRCC

DFF332 a novel HIF inhibitor

New IMDC risk group - very favorable

Another breakthrough perioperative

New HIF inhibitor in clear cell RCC

nccRCC

NIVO+CABO: significantly longer therapy-free time

Metastasized chromophobe RCC

The search of the ideal biomarker in advanced renal…

Adjuvant KIM-1 as prognostic & predictive biomarker

KIM-1 - old wine in new bottles

KIM-1: Will have a major impact

Treatment of favorable prognosis mRCC patients:…

Tratamiento del cancer renal avanzado de pronostico…

End of the story in EGFRm disease?

Gamechanger in EGFR-mutated NSCLC

Early change in SOC in EGFR+ LD-NSCLC

Perioperative chemotherapy and N2 status

4-year efficacy of Keynote-799 and ctDNA

ctDNA predicts outcome in patients treated with…

Confirmed efficacy of periop IO in N2 R-NSCLC

Stadium III EGFR+: now permanently Osimertinib?!

Osimertinib improves PFS in stage III

Liquid biopsy in curative situation

4y follow-up of CheckMate 816

4y follow-up de CheckMate 816

Cambio temprano en el tratamiento estándar del EGFR+…

Lorlatinib with extraordinary data in ALK + NSCLC

KRAS in NSCLC - a lot to come

TROP2-targeting ADCs: where a we heading?

Adagrasib for KRASG12C mutation 2nd line

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

EGFR+ NSCLC - amivantamab-based combination therapy

ASCO 2024 highlights

ADCs - moving landscapes. Subgroups remain to be…

KRASG12C - the story continues

KRAS building on single agent therapy

Telehealth is just as effective as a face-to-face visit…

ALK+ NSCLC - CROWN revisited

Lorlatinib convincing in ALK mutation 1st line

BAY2927088 - Promising Her2-Inhibitor in NSCLC

Confirmed efficacy of adagrasib in KRASG12C

The end for local therapy for oligometastatic disease

KRASG12C - het verhaal gaat verder

La télésanté est aussi efficace qu'une consultation…

ASCO 2024 highlights

Het einde van lokale therapie voor oligometastatische…

ASCO 2024 highlights

Tarlatamab shows activity in patients with brain…

LD-SCLC: What´s about PCI?

New SoC for LD-SCLC

Maintenance with durvalumab is the new SOC after…

Tot slot, verandering voor LS-SCLC

Harsh to beat

10 years follow up - immunotherapy for BRAF-mutated…

Is the triplet ready for phase 3?

Is adjuvant treatment still standard in macroscopic,…

Is the induction treatment the new strategy for…

Stimulating new combination of two antibody-cytokine…

Emerging rescue therapies for PD1 refractory melanoma

Identifying patients with longterm benefits during…

Progress in neoadjuvant therapy with IO

TIL therapy for metastatic melanoma

Survival data for TT with dabrafenib and trametinib

A new therapy benchmark for brain-met melanoma patients

Adjuvant therapy with dabrafenib and trametinib - final…

Promising Results: Triple combination therapy in…

No differences in PFS between the two study arms

Vaccine in combination with nivolumab for PDL1…

Neoadjuvant intratumoral therapy with Daromun in…

Impactful studies from ASCO 24 I: NADINA

Consolidation of the use of IO in clinically detectable…

Promising activity of brenetafusp in PD-L1 refractory…

A new triplet for metastatic melanoma

Impactful studies from ASCO 24 III: Cell-therapy

New oncolytic immunotherapy (RP1) after PD-1 failure

3-year update on mRNA vaccines in melanoma

Neoadjuvant immunotherapy treatment for melanoma

Intralesional therapy with Daromun

Longterm survival after adjuvant targeted therapy

mRNA vaccine plus pembrolizumab in adjuvant therapy

Triple checkpoint blockade - a new approach?

Impactful studies from ASCO 24 II: Combi-AD

Prometedora actividad de brenetafusp en melanoma…

Risultati promettenti: Tripla terapia di combinazione…

No hubo diferencias en la PFS entre los dos brazos del…

Encouraging developmental IO-options

New insights in localized HNSCC

New perspectives in HPV+ r/m HNSCC

De-escalation in ovarian cancer?

New idea: anti-digest for EC?